Cargando…
The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced
BACKGROUND: The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, for exampl...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838235/ https://www.ncbi.nlm.nih.gov/pubmed/34777865 http://dx.doi.org/10.1186/s43066-021-00082-y |
_version_ | 1783643128824070144 |
---|---|
author | Vitiello, Antonio La Porta, Raffaele D’Aiuto, Vilma Ferrara, Francesco |
author_facet | Vitiello, Antonio La Porta, Raffaele D’Aiuto, Vilma Ferrara, Francesco |
author_sort | Vitiello, Antonio |
collection | PubMed |
description | BACKGROUND: The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, for example, from a minimum of 0.05% in Singapore to a maximum of 9.75 in Mexico; however, mortality and severity of COVID-19 are higher in the elderly and in those with comorbidities already present such as diabetes, hypertension, and heart disease. MAIN TEXT: Recent evidence has shown that an underlying liver disease can also be a risk factor, and SARS-CoV-2 itself can cause direct or indirect damage to liver tissue through multisystem inflammation generated especially in the more severe stages. In the current pandemic, liver dysfunction has been observed in 14–53% of patients with severe COVID-19. In addition, drugs administered during infection may be an additional factor of liver damage. The mechanism of cellular penetration of the virus that occurs by viral entry is through the receptors of the angiotensin 2 conversion enzyme (ACE-2) host that are abundantly present in type II pneumocytes, heart cells, but also liver cholangiocytes. CONCLUSION: In this manuscript, we describe the clinical management aimed at preserving the liver or reducing the damage caused by COVID-19 and anti-COVID-19 drug treatments. |
format | Online Article Text |
id | pubmed-7838235 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-78382352021-01-28 The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced Vitiello, Antonio La Porta, Raffaele D’Aiuto, Vilma Ferrara, Francesco Egypt Liver Journal Review BACKGROUND: The global pandemic COVID-19 caused by the new coronavirus SARS-CoV-2 has already caused about 1.4 million deaths, and to date, there are no effective or direct antiviral vaccines. Some vaccines are in the last stages of testing. Overall mortality rates vary between countries, for example, from a minimum of 0.05% in Singapore to a maximum of 9.75 in Mexico; however, mortality and severity of COVID-19 are higher in the elderly and in those with comorbidities already present such as diabetes, hypertension, and heart disease. MAIN TEXT: Recent evidence has shown that an underlying liver disease can also be a risk factor, and SARS-CoV-2 itself can cause direct or indirect damage to liver tissue through multisystem inflammation generated especially in the more severe stages. In the current pandemic, liver dysfunction has been observed in 14–53% of patients with severe COVID-19. In addition, drugs administered during infection may be an additional factor of liver damage. The mechanism of cellular penetration of the virus that occurs by viral entry is through the receptors of the angiotensin 2 conversion enzyme (ACE-2) host that are abundantly present in type II pneumocytes, heart cells, but also liver cholangiocytes. CONCLUSION: In this manuscript, we describe the clinical management aimed at preserving the liver or reducing the damage caused by COVID-19 and anti-COVID-19 drug treatments. Springer Berlin Heidelberg 2021-01-27 2021 /pmc/articles/PMC7838235/ /pubmed/34777865 http://dx.doi.org/10.1186/s43066-021-00082-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Review Vitiello, Antonio La Porta, Raffaele D’Aiuto, Vilma Ferrara, Francesco The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title_full | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title_fullStr | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title_full_unstemmed | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title_short | The risks of liver injury in COVID-19 patients and pharmacological management to reduce or prevent the damage induced |
title_sort | risks of liver injury in covid-19 patients and pharmacological management to reduce or prevent the damage induced |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7838235/ https://www.ncbi.nlm.nih.gov/pubmed/34777865 http://dx.doi.org/10.1186/s43066-021-00082-y |
work_keys_str_mv | AT vitielloantonio therisksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT laportaraffaele therisksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT daiutovilma therisksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT ferrarafrancesco therisksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT vitielloantonio risksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT laportaraffaele risksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT daiutovilma risksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced AT ferrarafrancesco risksofliverinjuryincovid19patientsandpharmacologicalmanagementtoreduceorpreventthedamageinduced |